Cargando…

Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi

OBJECTIVE: To assess the effectiveness of Sofosbuvir (SOF) and Daclatasvir (DCV) in patients with chronic hepatitis C (CHC), compensated cirrhosis (CC) and decompensated cirrhosis (DCLD) either treatment naïve or experienced. METHODS: This was a prospective, observational study, conducted from Janua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butt, Nazish, Anoshia, Khan, Muhammad Ali, Akbar, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613042/ https://www.ncbi.nlm.nih.gov/pubmed/34912436 http://dx.doi.org/10.12669/pjms.37.7.4627

Ejemplares similares

Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan
por: Butt, Nazish, et al.
Publicado: (2019)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
por: Butt, Zamir, et al.
Publicado: (2019)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Efficacy and Safety of N-Butyl 2 Cyanoacrylate Injection for Treatment of Gastric Varices: A five year experience from a tertiary care hospital in Karachi, Pakistan
por: Butt, Nazish, et al.
Publicado: (2022)

Epidemiology, Clinical Characteristics, and Management Status of Hepatitis B: A Cross-sectional Study in a Tertiary Care Hospital at Karachi, Pakistan
por: Butt, Nazish, et al.
Publicado: (2019)

An Unusual Case of Congenital Hepatic Fibrosis with Retinitis Pigmentosa
por: Butt, Nazish, et al.
Publicado: (2019)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
por: Hassan, Amro M, et al.
Publicado: (2018)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Transcriptional Analysis of TP53 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, Pegylated Interferon, and Ribavirin
por: Chudhary, Hafiza Rida Farooq, et al.
Publicado: (2023)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
por: Rahman, Attiya S, et al.
Publicado: (2023)

Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)

Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
por: Ashraf, Taha, et al.
Publicado: (2017)

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017)

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
por: El-Shabrawi, Mortada HF, et al.
Publicado: (2019)

Syncope: experience at a tertiary care hospital in Karachi, Pakistan
por: Patel, Muhammad Junaid, et al.
Publicado: (2008)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study
por: Fayed, Hanan M., et al.
Publicado: (2019)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017)

Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis
por: Chan, Huan-Tee, et al.
Publicado: (2021)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
por: Shabani, M., et al.
Publicado: (2021)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol, Stanislas, et al.
Publicado: (2016)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
por: Mucenic, Marcos, et al.
Publicado: (2019)

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village
por: Ahmed, Ossama Ashraf, et al.
Publicado: (2018)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
por: Flower, Barnaby, et al.
Publicado: (2023)

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
por: Cheema, Shafiq Ur Rehman, et al.
Publicado: (2019)

Daclatasvir: potential role in hepatitis C
por: Lee, Choongho
Publicado: (2013)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
por: Ahmed, Ossama A, et al.
Publicado: (2018)

Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice
por: Margusino-Framiñán, Luis, et al.
Publicado: (2019)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
por: Duerr, Michael, et al.
Publicado: (2019)

The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats
por: Moustafa, Ahmed H., et al.
Publicado: (2023)

Frequency of Stillbirths in a Tertiary Care Hospital, Karachi
por: Mustufa, Muhammad Ayaz, et al.
Publicado: (2016)

Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
por: Ibraheem, Mohammad Fadhil, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q0t46e9adv504pct1ebarst65g